Effects of azacitidine combined with venetoclax on inflammatory markers and overall response rate in elderly patients with newly diagnosed acute myeloid leukemia.

Hui-Fang Liu, Cheng Lian, Xian-Guang Zhu

Abstract read

In one paragraph

Article in BMC geriatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Hui-Fang LiuDepartment of Clinical Laboratory, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, and People's Hospital of Henan University, No. 7 Weiwu Road, Jinshui District, Zhengzhou, Henan Province, 450003, China. Reneliu1024@163.com.

Cheng LianDepartment of Hematology, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, and People's Hospital of Henan University, Zhengzhou, Henan, 450003, China.

Xian-Guang ZhuDepartment of Clinical Laboratory, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, and People's Hospital of Henan University, No. 7 Weiwu Road, Jinshui District, Zhengzhou, Henan Province, 450003, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis study aimed to evaluate the impact of azacitidine (AZA) combined with venetoclax (VEN) compared to AZA monotherapy on systemic inflammatory markers and the overall response rate (ORR) in elderly patients with newly-diagnosed acute myeloid leukemia (AML) who were unfit for intensive chemotherapy.

methodsA retrospective cohort study included 205 patients (≥ 60 years) treated between January 2021 and June 2022. Patients received either AZA alone (n = 93) or AZA plus VEN (n = 112). Serum levels of C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α) were measured at baseline and after three treatment cycles. ORR was assessed using International Working Group criteria.

resultsThe combination therapy group showed significantly greater reductions in inflammatory markers (CRP, IL-6, TNF-α; all P < 0.001) and improved hematological recovery compared to monotherapy. ORR was higher with combination therapy (73.21% vs. 46.24%, P < 0.001). Baseline TNF-α > 70 pg/mL was independently associated with lower ORR (OR 0.589, P = 0.016). The incidence of adverse events did not differ significantly between groups.

conclusionAZA plus VEN was associated with significantly greater reductions in systemic inflammation and improved treatment responses compared to AZA monotherapy in elderly AML patients, without a significant increase in severe toxicity. These findings suggest that the combination regimen may be a promising first-line option for this population; however, prospective randomized trials are warranted to confirm these observations.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsAzacitidineBridged Bicyclo Compounds, HeterocyclicLeukemia, Myeloid, AcuteSulfonamidesAgedAged, 80 and overBiomarkersCohort StudiesC-Reactive ProteinFemaleHumansInterleukin-6MaleMiddle AgedRetrospective StudiesAzacitidineBiomarkersBridged Bicyclo Compounds, HeterocyclicC-Reactive ProteinInterleukin-6SulfonamidesTumor Necrosis Factor-alphavenetoclaxAcute myeloid leukemiaAzacitidineElderly patientsInflammationOverall response rateVenetoclax

Identifiers

PMID42919186

DOI10.1182/blood-2018-10-879866

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.